Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparative pharmacokinetics of biosimilar WT-1 trastuzumab vs reference trastuzumab in healthy males
TCTR20240704011Phase 1Terminated
- Sponsor
- Chulabhorn Foundation
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of trastuzumab (2 arms), sponsored by Chulabhorn Foundation. Started Sep 2025; status: terminated.
02
Drugs
Beyond the preview
Go deeper on TCTR20240704011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20240704011.